Nephrotoxic Drug Syndromes — Advanced

Drug-associated acute interstitial nephritis may present with AKI, pyuria, hematuria, rash, or fever, although the classic triad is often incomplete. A careful drug timeline and evaluation for competing causes are essential; biopsy may be needed when the diagnosis or treatment decision is uncertain.

Acute tubular injury is characterized by epithelial simplification, brush-border loss, dilation, detachment, and granular casts. These findings differ from immune-complex glomerular disease and should be interpreted with clinical timing and urine findings.

Aminoglycosides accumulate in proximal tubular cells and can cause dose- and duration-related tubular injury. Risk increases with repeated exposure, high concentrations, concomitant nephrotoxins, and reduced renal reserve, so monitoring and de-escalation are important.

Prompt withdrawal of a suspected culprit is a central intervention in drug-associated AIN, provided an appropriate alternative is available. The broader evaluation should exclude infection, obstruction, and other causes, with biopsy or corticosteroids considered in selected cases.

NSAIDs inhibit renal prostaglandin synthesis, reducing afferent arteriolar vasodilation, especially during volume depletion or reduced effective arterial volume. The risk is amplified when combined with diuretics and renin-angiotensin system blockade.

Proximal tubular dysfunction can cause phosphate wasting, normoglycemic glycosuria, bicarbonate loss, aminoaciduria, and tubular proteinuria. The pattern supports a proximal tubulopathy and should prompt review of exposure, duration, alternative agents, and kidney function.

Myoglobin or hemoglobin can produce a heme-positive dipstick with few red cells. Clinical context such as rhabdomyolysis or hemolysis, creatine kinase, plasma free hemoglobin, and sediment findings help distinguish pigment injury from glomerular inflammation.

Some drugs and metabolites precipitate in tubular fluid, particularly with high doses, low urine volume, or pre-existing impairment. Management includes stopping or changing the drug when possible, correcting volume status, and avoiding further nephrotoxic exposure.

No single urine biomarker reliably establishes AIN. Diagnostic reasoning integrates exposure timing, pyuria or WBC casts, rash or fever, hemodynamics, ultrasound, competing diagnoses, and, when management depends on certainty, biopsy.

A prior episode strongly raises concern for recurrence with re-exposure. The culprit should be documented clearly, alternatives selected, and future clinicians informed because recurrent interstitial inflammation can accelerate chronic scarring and reduce recovery.